Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)

China flag China · Delayed Price · Currency is CNY
10.81
-0.57 (-5.01%)
Jun 18, 2026, 3:04 PM CST
Market Cap10.27B -35.8%
Revenue (ttm)2.60B +0.3%
Net Income353.15M -50.4%
EPS0.36 -51.6%
Shares Out 950.40M
PE Ratio30.38
Forward PE10.18
Dividendn/a
Ex-Dividend Daten/a
Volume34,021,234
Open11.65
Previous Close11.38
Day's Range10.60 - 11.65
52-Week Range10.48 - 19.13
Beta0.44
AnalystsStrong Buy
Price Target19.62 (+81.5%)
Earnings DateAug 21, 2026

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cyt... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 2,755
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 000403
Full Company Profile

Financial Performance

In 2025, SHE:000403's revenue was 2.63 billion, a decrease of -0.83% compared to the previous year's 2.65 billion. Earnings were 419.27 million, a decrease of -43.75%.

Financial Statements